Extracellular Vesicles Derived from VEGF mRNA-Engineered Mesenchymal Stem Cells Promote Endothelial Cell Survival

Area of Science:

• Biomedical Engineering
• Regenerative Medicine
• Cell Biology

Background:

• Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) show therapeutic promise for ischemia-related conditions like myocardial infarction and stroke.
• Enhancing MSC-EV efficacy is crucial for advancing their clinical use.
• Vascular endothelial growth factor (VEGF) is key for angiogenesis and endothelial cell survival.

Purpose of the Study:

• To investigate engineering mesenchymal stem cells (MSCs) with vascular endothelial growth factor (VEGF) mRNA to enhance the therapeutic effects of their derived extracellular vesicles (EVs).
• To evaluate the impact of VEGF-engineered MSC-EVs on endothelial cell survival and therapeutic efficacy.

Main Methods:

• Engineered parent MSCs with VEGF mRNA.
• Quantified VEGF mRNA and protein levels in transfected MSCs and their derived EVs (VEGF-MSC-EVs).
• Assessed VEGF bioactivity via an angiogenesis assay.
• Evaluated the protective effects of VEGF-MSC-EVs against apoptosis in human umbilical vein endothelial cells (HUVECs).

Main Results:

• Transfected MSCs showed elevated VEGF mRNA and protein levels with demonstrated bioactivity.
• VEGF-MSC-EVs contained significantly higher levels of VEGF mRNA and protein compared to control MSC-EVs.
• VEGF-MSC-EVs exhibited superior protection of HUVECs from apoptosis compared to control MSC-EVs.

Conclusions:

• Engineering MSCs with VEGF mRNA successfully produced EVs with enhanced therapeutic properties.
• VEGF-MSC-EVs promote endothelial cell survival, offering a novel mechanism for improving therapeutic efficacy.
• This approach presents a promising cell-free therapy strategy for ischemia-associated diseases.